Bicycle Therapeutics (BCYC) Income towards Parent Company (2018 - 2026)

Bicycle Therapeutics (BCYC) has 9 years of Income towards Parent Company data on file, last reported at -$50.3 million in Q2 2026.

• Quarterly Income towards Parent Company rose 36.24% year-over-year to -$50.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$142.2 million (up 42.68% YoY) and the FY2025 annual result came in at -$170.8 million, up 2.32% from the prior year.
• Income towards Parent Company rose to -$50.3 million in Q2 2026, from -$60.9 million in the prior quarter.
• In the past five years, Income towards Parent Company ranged from a high of $28.1 million in Q4 2025 to a low of -$79.0 million in Q2 2025.
• A 5-year average of -$42.1 million and a median of -$46.1 million in 2023 frame the typical range for Income towards Parent Company.
• The widest YoY moves for Income towards Parent Company: up 148.66% in 2025, down 129.1% in 2025.
• Tracing BCYC's Income towards Parent Company over 5 years: stood at -$37.0 million in 2022, then sank by 34.01% to -$49.6 million in 2023, then retreated by 16.31% to -$57.6 million in 2024, then jumped by 148.66% to $28.1 million in 2025, then tumbled by 279.46% to -$50.3 million in 2026.
• The last three Income towards Parent Company figures came in at -$50.3 million (Q2 2026), -$60.9 million (Q1 2026), and $28.1 million (Q4 2025), per Business Quant data.